Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Epigenetic Reader Domain
    (362)
  • PROTACs
    (65)
  • Apoptosis
    (30)
  • Histone Acetyltransferase
    (18)
  • Histone Methyltransferase
    (14)
  • Autophagy
    (6)
  • Ligands for Target Protein for PROTAC
    (6)
  • CDK
    (5)
  • PI3K
    (5)
  • DNA/RNA Synthesis
    (4)
Filter
Search Result
Results for "

Epigenetic Reader Domain

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    365
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    4
    TargetMol | Peptide_Products
  • PROTAC Products
    97
    TargetMol | PROTAC
  • Natural Products
    9
    TargetMol | Natural_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
PROTAC BRD4 ligand-1
T125512313230-51-0In house
PROTAC BRD4 ligand-1, a component of Protac GNE-987, is a ligand for BRD4 and acts as an inhibitor of BET.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
A-485
T140731889279-16-6
A-485 is a potent and selective catalytic p300 CBP inhibitor with IC50 values of 9.8 nM for p300 and 2.6 nM for CBP.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
BY27
T106382247236-59-3In house
BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1 BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.
  • Inquiry Price
8-10 weeks
Size
QTY
CF53
T107731808160-52-2In house
CF53 is a highly potent, selective, and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2.2 nM, and an IC50 of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins with high affinities, being very selective over non-BET bromodomain-containing proteins. CF53 exhibits potent anti-tumor activity both in vitro and in vivo.
  • Inquiry Price
8-10 weeks
Size
QTY
CPI-0610 carboxylic acid
T108791380089-81-5In house
CPI-0610 carboxylic acid is an effective and selective small molecule inhibitor of bromine domain and outer end (BET) protein as a ligand of PROTAC target protein. CPI-0610 carboxylic acid may have anticancer and anticancer activities.
  • Inquiry Price
8-10 weeks
Size
QTY
OXFBD04
T123382231747-03-6In house
OXFBD04 is a potent and selective BRD4 inhibitor (IC50= 166 nM), a BET bromodomain ligand with modest affinity for the CREBBP bromodomain, and exhibits anti-cancer activity.
  • Inquiry Price
6-8 weeks
Size
QTY
ZEN-3694
ZEN3694, ZEN 3694
T292141643947-30-1In house
ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.
  • Inquiry Price
Size
QTY
Pocenbrodib
P-300, FT-7051
T696912304372-79-8In house
Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP p300 family with potential antitumour activity and is palatable for cancer research.
  • Inquiry Price
10-14 weeks
Size
QTY
TRIM24/BRPF1-IN-2
T742713033288-68-2In house
TRIM24 BRPF1-IN-2 is a selective dual TRIM24 BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.
  • Inquiry Price
Size
QTY
TCIP 1
T79801 In house
TCIP 1 is a small molecule in the category of transcriptional epigenetic covalent inhibitor probes (TCIPs) that forms covalent bonds with molecules targeting BCL6 and BRD4. This compound facilitates cell death gene expression by directing endogenous cancer drivers or transcription factors to the promoters of these genes. Additionally, TCIP 1 exhibits a gain-of-function mechanism, displaying both cell and tissue specificity, and it establishes a ternary complex with BCL6 and BRD4. It counteracts BCL6's inhibitory effect on apoptosis gene expression, leading to the activation of apoptosis. Furthermore, TCIP 1 markedly suppresses MYC oncogene expression and curtails the proliferation of diffuse large B-cell lymphoma (DLBCL) [1].
  • Inquiry Price
3-6 months
Size
QTY
Curcumin
Turmeric yellow, Natural Yellow 3, Indian Saffron, Diferuloylmethane
T1516458-37-7
Curcumin (Natural Yellow 3) is a phenolic natural product, an inhibitor of histone acetyltransferase p300 CREB (IC50=25 μM) with specificity. Curcumin has a wide range of pharmacological activities such as antitumor, anti-inflammatory and antioxidant.
  • Inquiry Price
Size
QTY
(+)-JQ-1
JQ1
T21101268524-70-4
(+)-JQ-1 (JQ1) is a specific, reversible BET bromine domain inhibitor that targets BRD4 (1 2) with IC50 values of 77 33 nM. (+)-JQ-1 induces cell autophagy and inhibits cell proliferation.
  • Inquiry Price
Size
QTY
3-methyl-1,2,3,4-tetrahydroquinazolin-2-one
T5000624365-65-9
3-methyl-1,2,3,4-tetrahydroquinazolin-2-one is a inhibitor of BRD4 .
  • Inquiry Price
Size
QTY
A-366
A366, A 366
T36241527503-11-2
A-366 is a highly selective peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP, respectively.It is more than 1,000-fold selective for G9a and GLP over the other 21 methyltransferases. It is an inhibitor of the Spindlin1-H3K4me3 interaction with an IC50 of 182.6 nM.It exhibits high affinity for human H3R with a Ki value of 17 nM, and shows subtype selectivity between subgroups of the histaminergic and dopaminergic receptor families.
  • Inquiry Price
Size
QTY
666-15
CREB inhibitor
T53181433286-70-4
666-15 is a selective CREB inhibitor with an IC50 of 81 nM. 666-15 can effectively inhibit the growth of breast cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
BI 2536
T6173755038-02-9
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
  • Inquiry Price
Size
QTY
CPI-637
CPI 637
T68111884712-47-3
CPI-637 is a selective and cell-active benzodiazepinone CBP EP300 bromodomain inhibitor.
  • Inquiry Price
Size
QTY
3-methyl-1,2-dihydroquinolin-2-one
T500352721-59-7
3-methyl-1,2-dihydroquinolin-2-one is the first known micromolar inhibitors of the ATAD2 bromodomain.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
BRD4 Inhibitor-20
T613182490311-14-1
BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity, demonstrating antiproliferative effects in cancer cell lines and used in studies of various cancers, including colon cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
Tz-Thalidomide
T779122087490-42-2
Tz-Thalidomide is a tetrazine-modified Thalidomide (E3 ligase ligand) with some affinity for BRD4.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
E-7386
E7386
T111361799824-08-0
E-7386 is an oral active CBP -catenin modulator.
  • Inquiry Price
Size
QTY
(s)-gne-987
T12798
(S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC).
  • Inquiry Price
Size
QTY
SNDX-5613
T129432169919-21-3
Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
tp-472
T131902079895-62-6
TP-472 is a selective inhibitor of BRD9 (Kd: 33 nM).
  • Inquiry Price
6-8 weeks
Size
QTY